Shamburg News · 8-K filed Oct 2, 2026, 8:05 AM EDT
Surrozen Announces FDA IND Clearance for SZN-8141 in Diabetic Macular Edema
SRZN · Surrozen, Inc./DE
- Other event
- Financing
- Materiality: high
Surrozen, Inc. announced on October 2, 2026 that the FDA cleared its IND application for SZN-8141, allowing clinical development to proceed after the 30-day review period. The company expects to dose the first patient in its Phase 1b/2a DUET study in the fourth quarter of 2026, with initial data expected in the second half of 2027. The IND clearance satisfies the second closing milestone under the March 2025 two-tranche private placement, which is expected to provide approximately $95.1 million in gross proceeds on or about October 20, 2026.
Source: SEC EDGAR, Form 8-K, Item 8.01, accession 0001193125-26-411298.
Written from the filing by Shamburg Markets. Figures are as reported by the company.